Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HMPL-306 in Grade 2 Glioma With IDH1/2 Mutations
NCT07912398Phase 3Not yet recruiting
- Sponsor
- HUTCHMED
- Start
- Nov 2026
- Primary completion
- Mar 2032
01
Overview
A Phase 3 trial of ranosidenib in glioma, sponsored by HUTCHMED. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
ranosidenib
03
Conditions
glioma
Beyond the preview
Go deeper on NCT07912398.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07912398.